Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03477903 · ClinicalTrials.gov registry record · Phase 2
TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03477903 is a Phase 2 study that was terminated before completion, run by Millennium Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT03477903, a Phase 2 study, was terminated before completion, sponsored by Millennium Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the treatment effect of intravenous TAK-954 in improving the average daily protein adequacy received through enteral nutrition in critically-ill participants developing EFI.
Interventions
- DRUG Normal Saline
- DRUG Metoclopramide
- DRUG TAK-954
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-08-25 |
| Est. Completion | 2018-08-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03477903
The ClinicalTrials.gov registry entry for NCT03477903 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Normal Saline is the first listed.
NCT03477903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03477903 about?
NCT03477903 is a clinical study titled "TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)". The purpose of this study is to assess the treatment effect of intravenous TAK-954 in improving the average daily protein adequacy received through enteral nutrition in critically-ill participants developing EFI.
What is the current status of trial NCT03477903?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2018-08-25. Estimated completion is 2018-08-29.
What interventions are being tested in trial NCT03477903?
The interventions under investigation include: Normal Saline (DRUG), Metoclopramide (DRUG), TAK-954 (DRUG).
Who is sponsoring clinical trial NCT03477903?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.